Introduction {#s001}
============

Regular and prolonged cannabis use has been associated with morphological^[@B1],[@B2]^ and functional brain changes,^[@B2]^ cognitive impairment,^[@B5]^ and increased risk of adverse mental health outcomes, including the precipitation of psychotic symptoms and disorders.^[@B6],[@B7]^ Neuroimaging evidence has consistently identified the hippocampus, a subcortical brain region critically involved in learning and memory and implicated in psychopathology, as a particular locus of compromise.^[@B1],[@B2]^ Long-term heavy cannabis users have demonstrated reduced hippocampal volume^[@B8],[@B9]^ and gray matter density^[@B10]^ compared to nonuser controls, with some evidence for greater volume loss resulting from greater exposure to cannabis.^[@B1]^ Alterations to hippocampal shape,^[@B11]^ neurochemistry,^[@B8]^ and structural^[@B12]^ and functional connectivity^[@B13]^ in chronic cannabis users have also been reported. Recently, we showed that volumetric reduction of specific hippocampal subfields (cornu ammonis \[CA\]1--4 and dentate gyrus \[DG\]) was sensitive to cannabis dependence, with an inverse correlation between greater lifetime cannabis exposure and subfield volumes in dependent, but not nondependent users.^[@B14]^

Cannabinoid type 1 receptors (CB1Rs) are abundant throughout the brain, but occur in high density in specific regions, including the hippocampus.^[@B15]^ Cannabis-related neurobiological, cognitive, and psychological harms are generally ascribed to Δ^9^-tetrahydrocannabinol (THC), the primary psychoactive constituent of cannabis, which is a partial agonist at CB1Rs.^[@B16],[@B17]^ Acute administration of THC to humans dose-dependently transiently increases anxiety, impairs cognition, and induces a range of positive and negative psychotic-like symptoms, including paranoia, delusions, and conceptual disorganization.^[@B18]^ While the precise mechanisms underlying these effects are not well understood, animal studies have shown that THC accumulates in neurons,^[@B21]^ with long-term exposure to THC resulting in neurotoxic changes in hippocampal microstructure.^[@B22]^ Conversely, cannabidiol (CBD) is the second most abundant cannabinoid in cannabis and has purported neuroprotective,^[@B23]^ anxiolytic,^[@B24]^ and antipsychotic^[@B25]^ properties. Acutely administered, CBD exerts opposing effects to THC upon activation of specific brain regions, including the hippocampus,^[@B26]^ and ameliorates the induction of hippocampal-dependent cognitive impairment and psychotic-like symptoms by THC in healthy volunteers.^[@B27]^ CBD has a low affinity for CB1Rs, yet demonstrates the capacity to antagonize CB1R agonists, which may underlie its functional antagonism of THC.^[@B28]^ Preclinical studies have shown CBD to induce synaptic plasticity and facilitate hippocampal neurogenesis,^[@B29],[@B30]^ with some evidence suggesting that the proneurogenic action of CBD via the hippocampus may underlie its anxiolytic effects.^[@B30]^ Although precise neurobiological mechanisms by which CBD may promote neurogenesis remain unclear, modulation of endocannabinoids such as anandamide through CB1Rs has been implicated.^[@B29],[@B31]^

In recent years, increasingly potent strains of cannabis containing high levels of THC and decreasing levels of CBD have dominated the market, raising concerns for greater THC-related harms in the community.^[@B7],[@B32]^ Naturalistic studies examining proportional exposure to THC and CBD by hair analysis of chronic cannabis users found that the presence of CBD in cannabis was associated with fewer psychotic-like symptoms,^[@B33],[@B34]^ improved recognition memory,^[@B34]^ and increased hippocampal gray matter concentration.^[@B10]^ We have recently shown apparent normalization of hippocampal volume and n-acetylaspartate (NAA; a marker of hippocampal neuronal integrity) levels in cannabis users regularly smoking cannabis containing CBD, such that they were indistinguishable from controls, while those exposed to THC but not CBD, showed 11% smaller hippocampal volumes and 15% lower NAA concentrations than controls.^[@B8]^ These findings indicate CBD may protect against neurobiological and psychological harms of regular cannabis use; however, the cross-sectional nature of these studies precludes any inferences about directionality.

The possibility that prolonged administration of CBD to cannabis users may protect against or reduce THC-induced harms is intriguing. The hippocampus is highly neuroplastic and volume growth has been demonstrated following relatively brief interventions (e.g., increase in hippocampal volume by 12% in patients with schizophrenia and 16% in healthy controls following 12 weeks of aerobic exercise,^[@B35]^ indicating this is an adequate timeframe to observe discernible treatment effects in the hippocampus). Hence, this study aimed to investigate whether prolonged administration of CBD may reverse hippocampal volumetric reduction typically observed in long-term, heavy cannabis users, but recruitment was broadened to enable examination of effects of CBD treatment in a sample with a range of cannabis experience. An ∼10-week pragmatic, open-label trial was undertaken, in which cannabis users within the community consumed 200 mg CBD in capsule form daily, in the context of their ongoing cannabis use. Structural magnetic resonance imaging (MRI) scans were completed at baseline and post-CBD treatment. It was hypothesized that prolonged CBD administration would result in increased hippocampal volume at post-treatment, as subserved by growth in specific subfields such as CA1, subiculum, and DG, due to the high concentration of CB1Rs in these subregions^[@B15]^ and their involvement in neurogenesis.^[@B36]^

Materials and Methods {#s002}
=====================

Participants {#s003}
------------

Twenty regular cannabis users (at least once per month for a minimum 6 months) aged 18--55 years were recruited from the community through newspaper and online advertisements. Exclusion criteria were current or past regular (greater than once per month for \>6 months in the past 3 years) other illicit drug use or dependence on or treatment-seeking for any substance other than cannabis; history of synthetic cannabinoid use; any neurological disorder or serious head injury; psychiatric history (assessed by the Mini-International Neuropsychiatric Interview Plus^[@B37]^) or medication use; pregnancy or lack of contraception for female cannabis users; and contraindications for MRI. Eighteen participants completed both baseline and post-treatment MRI scans and are reported in this study. Participants provided informed written consent at baseline, post-treatment, and each weekly session (see Procedure, CBD administration, and dose section), and were reimbursed for their participation. The study was approved by the University of Wollongong and Illawarra and Shoalhaven Local Health District Health and Medical Human Research Ethics Committee and registered as a clinical trial (ISRCTN89498802).

Procedure, CBD administration, and dose {#s004}
---------------------------------------

Further detail regarding the methodology of this pragmatic trial is provided by Solowij et al. (companion article^[@B38]^). In brief, participants attended two comprehensive testing sessions at the beginning (baseline) and completion (post-treatment) of ∼10 weeks of CBD administration, involving MRI scanning and other assessments (electroencephalography, neuropsychological, and clinical, not reported in this study). Participants were also required to attend brief weekly appointments throughout the trial for monitoring of physiological and psychological well-being, collection of blood and urine samples, and provision of CBD capsules. Participants were not asked to make any changes to their cannabis use patterns during the trial, but were instructed to abstain from cannabis, alcohol, and other substances for a minimum 12 h before baseline and post-treatment testing sessions. Participants were requested to abstain from use of illicit substances other than cannabis throughout the trial and were advised urine drug screens would be conducted to corroborate their self-report.^[@B38]^

At each weekly session, participants were provided 28 gelatin-coated capsules for oral administration containing 50 mg of 99.5% pure crystalline CBD (of herbal origin) solved in Miglyol 812 and Softisan 378 (Trigal Pharma Ltd.; BioSynthesis Pharma Group Ltd.). Participants were instructed to consume four capsules per day (100 mg in the morning and 100 mg in the evening, totaling 200 mg daily). This was selected as a "medium" dose in accordance with the range of therapeutic doses reported in human studies (e.g., 800--1000 mg/day well tolerated for up to 6 weeks in psychotic individuals^[@B39],[@B40]^), as well as for caution as no previous study had administered prolonged and relatively high doses of CBD to current cannabis users. Participants received an SMS text message each morning and evening reminding them to consume their capsules. At each weekly session, participants returned any unused capsules. Adherence was measured by participants self-reporting the times of any missed doses, using a Timeline Follow-Back Procedure,^[@B41]^ and corroborated by the number of capsules returned.

Measures {#s005}
--------

Participants\' demographic data were obtained and lifetime substance use quantified through structured interview. The Timeline Follow-Back Procedure^[@B41]^ was employed at baseline and each subsequent session to obtain a specific and accurate history of substance use throughout the trial (cumulative cannabis, alcohol, and tobacco use across the trial quantified). Cannabis use was converted to standardized units of "cones" (1 joint=3 cones; <https://cannabissupport.com.au/media/1593/timeline-followback.pdf>) for quantification. The Alcohol Use Disorders Identification Test,^[@B42]^ Severity of Dependence Scale,^[@B43]^ and Cannabis Withdrawal Scale^[@B44]^ were administered at baseline and post-treatment to assess extent of alcohol consumption, severity of cannabis dependence, and cannabis withdrawal symptoms from abstaining before the test session. Blood and urine samples were collected at each session to enable assay of CBD, THC, and THC metabolite concentrations in plasma^[@B45]^ (following trial completion), and for corroboration of self-reported substance use by urine toxicology.

Vocabulary and matrix reasoning subscales of the Wechsler Abbreviated Scale of Intelligence^[@B46]^ were administered at baseline to estimate full scale intelligence quotient (IQ). Psychological symptoms of depression, anxiety, and psychosis-proneness were assessed at baseline and post-treatment using the following standardized measures: Beck Depression Inventory^[@B47]^; State Trait Anxiety Index^[@B48]^; Community Assessment of Psychic Experiences^[@B49]^; and Cannabis Experiences Questionnaire (CEQ).^[@B50]^ Alternate forms of the Rey Auditory Verbal Learning Test (RAVLT),^[@B51]^ demonstrated to be sensitive to cannabis-related memory impairment,^[@B52],[@B53]^ were also administered at baseline and post-treatment.

MRI acquisition and processing {#s006}
------------------------------

Participants underwent structural MRI scans on a 3T Siemens Skyra with a 48-channel head and neck coil using a T1-weighted gradient echo sequence, MPRAGE, with 900 ms inversion time, TR/TE of 2300/2.1 ms, FA=9, 192 slices 1 mm thick, field of view=256×256 mm, and matrix=256×256, resulting in 1.0 mm isotropic resolution and a total acquisition time of 5 min and 26 sec. Participants also underwent other MRI scan sequences not reported in this study. T1-weighted images were processed using an automated longitudinal hippocampal subfield segmentation protocol available through FreeSurfer neuroimaging software version 6.0 (<https://surfer.nmr.mgh.harvard.edu>).^[@B54]^ This technique relies upon the creation of an unbiased subject-specific atlas, which each within-subject time point is then reprocessed against, to reduce within-subject variability.^[@B55]^ Furthermore, it has demonstrated greater sensitivity in identifying subtle hippocampal subregional changes than previous cross-sectional processing methods.^[@B54]^ Images were first processed through the longitudinal FreeSurfer stream,^[@B55]^ involving motion correction, skull stripping, intensity normalization, Talairach transformation, atlas registration, estimation of total intracranial volume, segmentation of white and gray matter volumes, and parcellation of subcortical structures, including the hippocampus. Hippocampal segmentation was then applied, generating volumes for whole left and right hippocampi as well as 12 subfields for each (parasubiculum, presubiculum, subiculum, CA1, CA2/3, CA4, granule cells in the molecular layer of the dentate gyrus \[GC-ML-DG\], hippocampal-amygdala transition area, fimbria, molecular layer of the dentate gyrus \[ML-DG\], hippocampal fissure, and hippocampal tail), as depicted in [Figure 1](#f1){ref-type="fig"}.

![Cross-sectional slices of a T1-weighted image from one participant with automated segmentation of hippocampal subfields overlaid. Coronal (top), axial (middle), and sagittal (bottom) views. CA, cornu ammonis; GC-ML-DG, granule cells in the molecular layer of the dentate gyrus; HATA, hippocampal-amygdala transition area; ML-DG, molecular layer of the dentate gyrus.](fig-1){#f1}

Statistical analyses {#s007}
--------------------

Statistical analyses were performed using SPSS version 21.0. Paired *t*-tests were conducted to assess volumetric change from baseline to post-treatment for total left and right hippocampal volumes and for the 12 subfields comprising each. As this was a novel exploratory pilot study in a small sample with no placebo control, no adjustment was made for multiple comparisons. Correlations examined associations between change in hippocampal subregion volume (post-treatment minus baseline volume, in mm^3^) and plasma CBD concentration, substance use parameters, psychological symptom, and cognitive measures. Outcomes were further explored by group (heavy versus light users, formulated by median split on lifetime cannabis use) using repeated-measures analysis of covariance (ANCOVA).

Results {#s008}
=======

Demographic, substance use, and psychological symptom characteristics of the sample are summarized in [Table 1](#T1){ref-type="table"}. Participants were predominantly young adult males (median age 25 years; four females), most of whom had completed some tertiary education. Participants had used cannabis regularly for a median of 5.17 years and at baseline were smoking cannabis a median of 25.75 days per month. Cannabis frequency and quantity measures did not significantly differ from baseline to post-treatment, indicating that a consistent level of cannabis use was maintained by participants throughout the trial. Most participants refrained from other illicit drug use during the trial^[@B38]^ (the one exception was not an outlier on any hippocampal measures and his data were retained in the analyses reported in this study). Median CBD capsule adherence was 93.16% (range 68.67--99.35%). Participants reported experiencing less euphoria when smoking cannabis (lower CEQ Euphoria scores) at post-treatment compared to baseline (*p*=0.001). Changes in other psychological symptoms and cognition from baseline to post-treatment in this sample are provided in [Table 1](#T1){ref-type="table"} and reported in detail in a slightly larger sample by Solowij et al.^[@B38]^

###### 

**Participant Demographic Data, Substance Use Measures, and Psychological Symptoms at Baseline and Post-Treatment**

                                                                   Baseline                 Post-treatment        *t*/Z^[a](#tf4){ref-type="table-fn"}^   *p*                                      Effect size (*d*/*r*)
  ---------------------------------------------------------------- ------------------------ --------------------- --------------------------------------- ---------------------------------------- -----------------------
  Age (years)                                                      25.07 \[20.56--46.83\]   ---                                                                                                     
  Gender (male/female)                                             14/4                     ---                                                                                                     
  Handedness (left/right)                                          2/16                     ---                                                                                                     
  Education (years)                                                15.50 \[11.00--17.50\]   ---                                                                                                     
  IQ                                                               114.44 (9.50)            ---                                                                                                     
  BMI                                                              22.68 (2.96)             ---                                                                                                     
  Alcohol frequency (days/month)                                   3 \[0--14\]              6 \[0--21\]           −1.95                                   0.051^[†](#tf3){ref-type="table-fn"}^    0.33
  Alcohol quantity (standard drinks/month)                         15.50 \[0--102\]         27.50 \[0--127.50\]   −1.22                                   0.222                                    0.20
  Cumulative alcohol quantity across the trial (standard drinks)   ---                      97.54 (75.76)                                                                                           
  AUDIT                                                            7.83 (5.10)              7.56 (4.97)           0.57                                    0.579                                    0.13
  Regular smoker (yes/no)                                          8/10                     ---                                                                                                     
  Tobacco frequency (days/month)                                   0.50 \[0--30\]           5.50 \[0--30\]        −1.48                                   0.138                                    0.25
  Tobacco quantity (cigarettes/month)                              2.50 \[0--300\]          8.75 \[0--225\]       −0.66                                   0.508                                    0.11
  Cannabis use                                                                                                                                                                                      
   Age of first use (years)                                        17.09 (2.18)             ---                                                                                                     
   Age of onset regular use (years)                                19.76 (2.11)             ---                                                                                                     
   Duration regular use (years)                                    5.17 \[0.56--28.83\]     ---                                                                                                     
   Estimated lifetime occasions of use (days)                      1734 \[141--8708\]       ---                                                                                                     
   Past month frequency (days/month)                               25.75 \[2--30\]          30.00 \[3--30\]       −1.67                                   0.096^[†](#tf3){ref-type="table-fn"}^    0.28
   Past month quantity (cones)                                     177.50 \[9--1125.00\]    165 \[8--1080.00\]    −0.60                                   0.551                                    0.10
   Cumulative quantity across the trial (cones)                    ---                      438 \[9.50--2195\]                                                                                      
   SDS                                                             3.33 (2.47)              3.11 (2.19)           0.56                                    0.586                                    0.13
   BDI                                                             2 \[0--14\]              0.50 \[0--12\]        −2.18                                   0.029^[\*](#tf2){ref-type="table-fn"}^   0.36
   STAI state                                                      25.72 (5.15)             29.39 (8.24)          −2.53                                   0.022^[\*](#tf2){ref-type="table-fn"}^   0.67
   STAI trait                                                      32 \[20--63\]            32 \[20--49\]         −1.52                                   0.129                                    0.25
   CAPE total frequency                                            59.83 (10.18)            56.67 (9.13)          1.99                                    0.063^[†](#tf3){ref-type="table-fn"}^    0.47
   CAPE total distress                                             23.78 (16.40)            19.39 (12.68)         2.09                                    0.052^[†](#tf3){ref-type="table-fn"}^    0.54
   CEQ Euphoria                                                    44.28 (7.78)             38.94 (6.81)          3.90                                    0.001^[\*](#tf2){ref-type="table-fn"}^   0.93
   RAVLT words recalled trials 1--5                                52.59 (11.52)            55.41 (9.96)          −1.88                                   0.079^[†](#tf3){ref-type="table-fn"}^    0.47

Mean (SD) or median \[range\].

*p*\<0.05.

Trend-level significance.

Paired samples *t*-test for normally distributed data; Wilcoxon signed-rank test for nonparametric data.

AUDIT, Alcohol Use Disorders Identification Test^[@B42]^; BDI, Beck Depression Inventory^[@B47]^; BMI, body mass index; CAPE, Community Assessment of Psychic Experiences^[@B49]^; CEQ, Cannabis Experiences Questionnaire^[@B50]^; IQ, intelligence quotient; SD, standard deviation; SDS, Severity of Dependence Scale^[@B43]^; STAI, State Trait Anxiety Index^[@B48]^; RAVLT, Rey Auditory Verbal Learning Task.^[@B51]^

Mean and significance values of all hippocampal volumetric comparisons are presented in [Table 2](#T2){ref-type="table"}. Paired samples *t*-tests revealed no significant change in total left or right hippocampal volume, nor in nine hippocampal subfields. However, a significant increase in left parasubiculum volume was observed (*p*=0.035), with trend-level increases in the left presubiculum (*p*=0.058) and left subiculum (*p*=0.066). In addition, a trend toward decreased volume in the right presubiculum was found (*p*=0.056). Subsequently, to increase reliability, total volumes of all subicular subfields (parasubiculum, presubiculum, and subiculum) were pooled to create a "subicular complex"^[@B56],[@B57]^ for each hemisphere. Paired samples *t*-tests showed a significant increase in left subicular complex volume (*p*=0.017; Cohen\'s *d*=0.63), but no change in the right subicular complex (*p*=0.471; Cohen\'s *d*=0.17). Changes in left and right subicular complex and substructures are detailed in [Table 3](#T3){ref-type="table"}.

###### 

**Hippocampal Whole and Subfield Volumes (mm^3^) at Baseline and Post-Treatment**

                        Baseline           Post-treatment     *p*
  --------------------- ------------------ ------------------ ----------------------------------------
  Whole hippocampus                                           
   Left                 3940.65 (333.06)   3962.13 (344.81)   0.180
   Right                4127.15 (356.02)   4119.00 (375.98)   0.682
  Subicular complex                                           
   Left                 885.18 (81.89)     899.17 (85.15)     0.017^[\*](#tf7){ref-type="table-fn"}^
   Right                865.83 (99.15)     862.06 (102.53)    0.471
  Parasubiculum                                               
   Left                 64.36 (9.79)       66.18 (10.57)      0.035^[\*](#tf7){ref-type="table-fn"}^
   Right                64.97 (12.77)      64.29 (12.11)      0.418
  Presubiculum                                                
   Left                 342.48 (24.29)     347.77 (24.62)     0.058^[†](#tf8){ref-type="table-fn"}^
   Right                334.71 (44.03)     330.36 (46.80)     0.056^[†](#tf8){ref-type="table-fn"}^
  Subiculum                                                   
   Left                 478.33 (60.32)     485.22 (62.14)     0.066^[†](#tf8){ref-type="table-fn"}^
   Right                466.15 (49.03)     467.40 (51.55)     0.697
  CA1                                                         
   Left                 706.73 (73.16)     710.41 (77.20)     0.322
   Right                750.62 (73.80)     754.35 (78.14)     0.380
  CA2/3                                                       
   Left                 252.73 (42.57)     254.05 (42.93)     0.371
   Right                284.33 (33.23)     283.08 (34.48)     0.533
  CA4                                                         
   Left                 326.63 (41.35)     326.89 (40.76)     0.911
   Right                353.30 (46.98)     352.50 (49.61)     0.760
  GC-ML-DG                                                    
   Left                 360.98 (40.63)     360.80 (40.24)     0.935
   Right                383.47 (45.14)     383.72 (48.72)     0.931
  HATA                                                        
   Left                 62.54 (8.67)       62.76 (8.97)       0.812
   Right                65.30 (6.82)       64.78 (7.02)       0.359
  Fimbria                                                     
   Left                 96.37 (15.78)      97.26 (15.77)      0.482
   Right                92.46 (23.75)      92.11 (23.58)      0.848
  ML-DG                                                       
   Left                 667.82 (61.27)     670.34 (61.26)     0.450
   Right                695.79 (60.06)     698.67 (64.04)     0.413
  Hippocampal fissure                                         
   Left                 155.92 (27.44)     157.35 (21.56)     0.725
   Right                156.50 (18.92)     152.37 (20.76)     0.379
  Hippocampal tail                                            
   Left                 581.66 (62.20)     580.44 (63.11)     0.777
   Right                636.05 (71.03)     627.74 (66.95)     0.126

Mean (SD) and paired *t*-test significance values. Subicular complex is the sum of parasubiculum, presubiculum, and subiculum volumes.

*p*\<0.05.

Trend-level significance.

CA, cornu ammonis; GC-ML-DG, granule cells in the molecular layer of the dentate gyrus; HATA, hippocampal-amygdaloid transition area; ML-DG, molecular layer of the dentate gyrus.

###### 

**Percentage Change in Volume from Baseline to Post-Treatment and Effect Sizes for Left and Right Subicular Complex and Substructures**

                            \% change   Effect size (*d)*
  ------------------------- ----------- -------------------
  Left subicular complex    1.58        0.63
   Left parasubiculum       2.83        0.55
   Left presubiculum        1.54        0.48
   Left subiculum           1.44        0.47
  Right subicular complex   −0.44       0.17
   Right parasubiculum      −1.05       0.20
   Right presubiculum       −1.30       0.51
   Right subiculum          0.27        0.10

\% change calculated as (\[post-treatment volume--baseline volume\]/baseline volume)×100.

Correlations did not reveal any significant association between left subicular complex or subregion volume change and plasma CBD concentration, cumulative CBD dose (calculated by number of capsules returned by participants), or weeks of CBD treatment. Right subicular complex volumetric change was significantly correlated with plasma CBD concentration in the final trial week (*ρ*=0.62, *p*=0.006), as well as a trend-level association with mean CBD plasma concentration over the trial (*ρ*=0.45, *p*=0.064), suggesting that higher plasma CBD was associated with increased growth in this area, despite the overall tendency toward a decrease in this region from baseline to post-treatment ([Table 3](#T3){ref-type="table"}). Age was not significantly correlated with any subicular change, other than at trend level in the left parasubiculum (*ρ*=−0.43, *p*=0.073), indicating growth in this subregion was more pronounced in younger participants, potentially implicating a role of brain maturation. Subicular complex or subregion volume change did not significantly correlate with any substance use measures; importantly, change in left subicular complex volume was not associated with changes in alcohol use frequency or quantity from baseline to post-treatment (both *p*\>0.601), nor with cumulative quantity of cannabis, alcohol, or cigarettes used over the trial (all *p*\>0.114). Left subiculum volume was correlated with lifetime duration of cannabis use at baseline (*ρ*=−0.54, *p*=0.021; trend for left subicular complex volume *ρ*=−0.44, *p*=0.066), suggesting that smaller volumes at baseline were associated with greater cannabis exposure, and these normalized with CBD treatment. A significant inverse correlation was observed between change in right subiculum volume and change in desired level of intoxication when smoking cannabis (scale 1--10 \[what level of intoxication do you usually like to reach?\], which tended to decrease from baseline to post-treatment: 7.14 vs. 6.97, respectively; *r*=−0.51, *p*=0.031; trend level also for left parasubiculum, *r*=−0.43, *p*=0.074; and left subicular complex, *r*=−0.42, *p*=0.080). This suggests that increased volume in these subicular regions was associated with lesser desired level of "high" following CBD treatment. No significant correlations between subicular complex or subregion volumes and psychological symptom or cognitive (RAVLT) measures were found.

Hippocampal volume change was further explored between and within groups of heavy and light users (median split on lifetime occasions of use, *n*=9 \[seven male, eight right handed\] each). Group differences in cannabis use measures are presented in [Table 4](#T4){ref-type="table"}. Heavy and light users significantly differed on lifetime cannabis use, frequency and quantity of cannabis use at baseline and post-treatment, cumulative cones smoked across the trial, as well as years of education (median years: heavy=12.50 and light=16.00; *p*=0.003), but did not differ in age (*p*=0.070) or IQ (*p*=0.056), any plasma CBD concentration measure (all *p*\>0.063), nor in alcohol or tobacco use or change over the trial (all *p*\>0.136). Years of education was not correlated with any hippocampal volume measure, so was not included as a covariate in analyses. Heavy and light users did not significantly differ on any hippocampal total or subregion volume measure at baseline, other than at trend level for the left fimbria (*p*=0.056). Repeated-measures ANCOVAs were conducted with group as a between-subjects factor and intracranial volume and cumulative cones smoked across trial as covariates. As reported in [Table 5](#T5){ref-type="table"}, no significant main effects of time were found for any total hippocampal or subregion volume. However, significant time by group interactions were observed in the left presubiculum (*p*=0.015) and right CA1 (*p*=0.012). [Figure 2a and 2b](#f2){ref-type="fig"} depict a marked increase in volume in these subregions from baseline to post-treatment in heavy users, yet a slight decrease in lighter users, with both groups showing more similar volume post-treatment. *Post hoc* repeated measures ANCOVAs (controlling for cumulative cannabis use across the trial) were performed within heavy and light user groups separately. Significant main effects of time were found only in heavy users for the left presubiculum (*p*\<0.001; light users *p*=0.80), left subicular complex (*p*=0.003; light users *p*=0.393), and trend level for left subiculum (*p*=0.064; light users *p*=0.344), indicating that the overall finding of increased left subicular complex volume across the trial was driven by the heavy user group. In addition, a significant main effect of time was observed in heavy users for the right CA1 (*p*=0.036; light users *p*=0.577).

![Time by group interaction for **(a)** left presubiculum (\**p*=0.015) and **(b)** right CA1 (\**p*=0.012) volume, controlling for intracranial volume and cumulative cannabis use (cones smoked) across the trial. Error bars represent standard error.](fig-2){#f2}

###### 

**Heavy and Light User Group Differences in Cannabis Use Measures**

                                                 Heavy (*n*=9)                  Light (*n*=9)                *Z*     *p*
  ---------------------------------------------- ------------------------------ ---------------------------- ------- -------------------------------------------
  Duration regular use (years)                                                                                        
   Baseline                                      6.53 \[4.13--28.83\]           3.39 \[0.56--5.53\]          −3.18   \<0.001^[\*](#tf12){ref-type="table-fn"}^
  Estimated lifetime occasions of use (days)                                                                          
   Baseline                                      2608.50 \[1734.00--8707.91\]   452.00 \[141.00--1448.00\]   −3.58   \<0.001^[\*](#tf12){ref-type="table-fn"}^
  Past month frequency (days/month)                                                                                   
   Baseline                                      30.00 \[9.00--30.00\]          12.00 \[2.00--30.00\]        −2.68   0.006^[\*](#tf12){ref-type="table-fn"}^
   Post-treatment                                30.00 \[13.00--30.00\]         16.00 \[3.00--30.00\]        −2.62   0.010^[\*](#tf12){ref-type="table-fn"}^
  Past month quantity (cones)                                                                                         
   Baseline                                      375.00 \[75.00--1125.00\]      42.00 \[9.00--463.75\]       −2.48   0.011^[\*](#tf12){ref-type="table-fn"}^
   Post-treatment                                472.50 \[58.50--1080.00\]      55.00 \[8.00--600.00\]       −2.56   0.008^[\*](#tf12){ref-type="table-fn"}^
  Cumulative quantity across the trial (cones)                                                                        
   Post-treatment                                1282.00 \[317.00--2195.00\]    113.00 \[9.50--815.00\]      −2.96   0.002^[\*](#tf12){ref-type="table-fn"}^

Median \[range\] and Wilcoxon signed-rank test significance values.

*p*\<0.05.

###### 

**Adjusted Mean (Standard Error) of Hippocampal Whole and Subfield Volumes for Heavy and Light User Groups**

                        Heavy (*n*=9)     Light (*n*=9)                                                                                  
  --------------------- ----------------- ----------------- ----------------- ----------------- ---------------------------------------- -----------------------------------------
  Whole hippocampus                                                                                                                      
   Left                 3822.57 (60.57)   3872.15 (62.23)   4058.73 (60.57)   4052.10 (62.23)   0.197                                    0.198
   Right                4025.95 (71.47)   4036.63 (68.91)   4228.35 (71.47)   4201.36 (68.91)   0.157                                    0.507
  Subicular complex                                                                                                                      
   Left                 857.42 (20.96)    884.06 (22.77)    912.94 (20.96)    914.28 (22.77)    0.683                                    0.104
   Right                871.28 (22.48)    865.40 (20.59)    860.38 (22.48)    858.71 (20.59)    0.254                                    0.780
  Parasubiculum                                                                                                                          
   Left                 61.74 (3.30)      62.71 (3.74)      66.98 (3.30)      69.64 (3.74)      0.591                                    0.471
   Right                66.50 (2.69)      65.56 (2.16)      63.44 (2.69)      63.03 (2.16)      0.195                                    0.322
  Presubiculum                                                                                                                           
   Left                 336.55 (9.00)     350.70 (9.00)     348.41 (9.00)     344.83 (9.00)     0.752                                    0.015^[\*](#tf14){ref-type="table-fn"}^
   Right                336.50 (14.10)    334.65 (14.92)    332.93 (14.10)    326.07 (14.92)    0.341                                    0.436
  Subiculum                                                                                                                              
   Left                 459.13 (15.99)    470.64 (16.76)    497.54 (16.76)    499.80 (16.76)    0.612                                    0.375
   Right                468.29 (9.99)     465.20 (8.04)     464.01 (9.99)     469.61 (8.04)     0.977                                    0.829
  CA1                                                                                                                                    
   Left                 678.61 (15.72)    686.20 (16.18)    734.85 (15.72)    734.63 (16.18)    0.064^[†](#tf15){ref-type="table-fn"}^   0.424
   Right                714.39 (15.91)    731.81 (18.79)    786.84 (15.91)    776.89 (18.79)    0.119                                    0.012^[\*](#tf14){ref-type="table-fn"}^
  CA2/3                                                                                                                                  
   Left                 238.72 (12.66)    240.03 (12.30)    266.74 (12.66)    268.08 (12.30)    0.390                                    0.995
   Right                273.97 (9.03)     271.91 (8.77)     294.69 (9.03)     294.25 (8.77)     0.347                                    0.788
  CA4                                                                                                                                    
   Left                 313.37 (10.03)    313.59 (9.16)     339.90 (10.03)    340.20 (9.16)     0.409                                    0.990
   Right                333.44 (12.77)    334.74 (13.22)    373.17 (12.77)    370.26 (13.22)    0.140                                    0.573
  GC-ML-DG                                                                                                                               
   Left                 346.29 (9.99)     347.79 (9.24)     375.68 (9.99)     373.81 (9.24)     0.400                                    0.614
   Right                364.66 (11.43)    368.37 (11.87)    402.29 (11.43)    399.07 (11.87)    0.085^[†](#tf15){ref-type="table-fn"}^   0.378
  HATA                                                                                                                                   
   Left                 59.46 (2.85)      60.61 (3.46)      65.63 (2.85)      64.92 (3.46)      0.486                                    0.453
   Right                63.67 (2.19)      62.73 (2.46)      66.94 (2.19)      66.83 (2.46)      0.523                                    0.631
  Fimbria                                                                                                                                
   Left                 88.24 (4.83)      88.38 (4.77)      104.50 (4.83)     106.14 (4.77)     0.836                                    0.697
   Right                86.02 (8.33)      81.41 (7.80)      98.90 (8.33)      102.81 (7.80)     0.201                                    0.055^[†](#tf15){ref-type="table-fn"}^
  ML-DG                                                                                                                                  
   Left                 647.81 (13.35)    655.02 (12.26)    687.84 (13.35)    685.65 (12.26)    0.164                                    0.304
   Right                679.17 (11.95)    689.94 (13.56)    712.41 (11.95)    707.41 (13.56)    0.224                                    0.106
  Hippocampal fissure                                                                                                                    
   Left                 160.18 (10.97)    157.78 (9.29)     151.66 (10.97)    156.91 (9.29)     0.365                                    0.501
   Right                159.09 (8.39)     149.02 (8.84)     153.92 (8.39)     155.72 (8.84)     0.159                                    0.370
  Hippocampal tail                                                                                                                       
   Left                 592.66 (25.66)    596.47 (25.11)    570.66 (25.66)    564.41 (25.11)    0.661                                    0.426
   Right                639.38 (29.88)    630.33 (27.22)    632.72 (29.88)    625.14 (27.22)    0.416                                    0.926

Repeated measures ANCOVA main effect of time and time by group interactions, controlling for intracranial volume and cumulative cannabis use (cones smoked) across the trial. Subicular complex is the sum of parasubiculum, presubiculum, and subiculum volumes.

*p*\<0.05.

Trend-level significance.

Exploratory correlations within heavy and light user groups separately indicated associations with mean, maximum, and final trial week plasma CBD concentrations in heavy users only, for the right subicular complex (CBD plasma: mean, *r*=0.71, *p*=0.032; maximum, *r*=0.68, *p*=0.045; and final week, *ρ*=0.82, *p*=0.007), right presubiculum (mean, *r*=0.85, *p*=0.003; maximum, *r*=0.69, *p*=0.040; and final week, *ρ*=0.70, *p*=0.036), and right subiculum (final week, *ρ*=0.68, *p*=0.042), indicating greater positive change (increased volumes) with higher CBD concentrations ([Fig. 3a, b](#f3){ref-type="fig"}). In heavy users, final week CBD plasma was also correlated with change in the whole right hippocampus (*ρ*=0.87, *p*=0.002, as shown in [Fig. 3c](#f3){ref-type="fig"}; *p*=0.002 also with removal of outlier) and in the right GC-ML-DG (*ρ*=0.70, *p*=0.036), and trend level with right CA1 change (*ρ*=0.63, *p*=0.067), suggesting that growth in these areas may be CBD treatment related.

![Significant associations in heavy users between **(a)** mean plasma CBD concentration and right presubiculum volume change; **(b)** mean plasma CBD concentration and right subicular complex volume change; and **(c)** final week CBD plasma concentration and right total hippocampal volume change. CBD, cannabidiol.](fig-3){#f3}

Discussion {#s009}
==========

This study reports outcomes from the first trial of prolonged CBD treatment to cannabis users within the community. We performed an automated longitudinal hippocampal subfield segmentation to examine the potential for chronic CBD administration to restore characteristic hippocampal volumetric reduction in regular cannabis users. We found an overall significant increase of left subicular complex volume from baseline to post-treatment, subserved by growth in the left parasubiculum, presubiculum, and subiculum, with medium-large effect sizes. We compared heavy and light users to explore the influence of prior cannabis exposure on CBD treatment outcomes, finding that the increased left subicular complex volume was driven by heavy users, particularly the marked growth that occurred in the left presubiculum, which normalized post-treatment volumes toward those observed in light users. Similarly, only heavy users showed a significant increase in right CA1 volume over the trial. Despite an overall trend toward decreased right presubiculum volume from baseline to post-treatment, significant associations between higher plasma CBD concentration and increased growth in this region were apparent, particularly in heavy users. Plasma CBD concentration was also significantly correlated with right subicular complex and total right hippocampal growth in heavy users.

These findings suggest a regionally specific restorative effect of CBD upon the subicular and CA1 subfields for heavy cannabis users, in the context of ongoing and relatively consistent cannabis use during the trial. The subicular subregions receive projections from CA1 and function as the primary hippocampal output structures, interfacing with the entorhinal cortex and a range of cortical and subcortical sites.^[@B58]^ Functionally, CA1 neurons are critically involved in the representation of temporal and spatial contextual information and retrieval of episodic memory,^[@B59],[@B60]^ while a dorsal-ventral functional segmentation has been suggested for subicular subregions, whereby dorsal subiculum is involved in spatial representation and memory and ventral subiculum is involved in hypothalamic--pituitary--adrenal regulation of stress, anxiety, and reward.^[@B61]^

Subicular and CA1 subregions are implicated in pathophysiological models of various conditions.^[@B62]^ For example, atrophy of the presubiculum, subiculum, and CA1 are the earliest sites of hippocampal degeneration in Alzheimer\'s disease^[@B62]^; subiculum, presubiculum, and right CA1 volume reduction have been demonstrated in patients with schizophrenia^[@B65]^ and bipolar disorder;^[@B65]^ and subiculum and CA1 shape alterations have been found in patients with major depressive disorder^[@B68],[@B69]^ and schizophrenia^[@B70]^ relative to healthy controls. Substantial evidence has revealed a pattern of progressive hippocampal pathophysiology in patients with schizophrenia, beginning with extracellular glutamate dysregulation driving hypermetabolism in CA1, which precipitates attenuated psychotic symptoms, and extends to the subiculum during the transition to frank psychosis.^[@B71]^ Longitudinal studies in ultra-high-risk patients have demonstrated focal atrophy of CA1, at a rate of 6% per year, differentiates those who progress onto syndromal psychosis and those whose attenuated psychotic symptom remit, with an extension of atrophy to the subiculum then other subfields as the illness progresses.^[@B73],[@B74]^ The rate of CA1 volume reduction specifically was found to predict worsening of symptom severity over time,^[@B74]^ highlighting the importance of preventing degeneration in this subregion. Furthermore, in schizophrenia patients, subiculum volume reduction has been associated with increased negative symptoms,^[@B65]^ and left presubiculum atrophy has been correlated with impairments in episodic memory.^[@B75]^

Interestingly, 12 weeks of antipsychotic treatment was found to increase subicular (but not CA1) volume (encompassing all subicular subregions) by an average 32 mm^3^ (2.55%) in patients experiencing a first-episode psychosis, while a healthy young adult control group (of a similar age to the sample reported in this study; mean \[standard deviation\]: 22.2 \[4.9\]) showed negligible change in this region (−0.53%) over the same period.^[@B76]^ This suggests natural fluctuation in subicular volume or the influence of ongoing brain maturation across our similar trial length and participant sample is unlikely, supporting a CBD treatment effect. Given the parallels observed in schizophrenia pathophysiology and neurobiological changes conferred by chronic cannabis use,^[@B77],[@B78]^ and interest in the antipsychotic properties of CBD,^[@B25]^ our finding of volumetric restoration in the subicular and CA1 regions is promising, and this therapeutic indication for CBD may extend to benefitting other clinical groups (e.g., schizophrenia).

The greater volumetric increase in heavy cannabis users is consistent with psychological symptom and cognitive outcomes from this trial, showing that dependent users experienced a significantly greater reduction in depressive and psychotic-like symptoms and improved cognition compared to nondependent users (reporting on *n*=20 participants^[@B38]^). In addition, we recently demonstrated protective effects of chronic CBD treatment against the development of negative psychotic-like symptoms in a preclinical model of schizophrenia, with no effect in control animals.^[@B79]^ While a ceiling effect may have occurred in lighter users, our findings nevertheless provide further support for the contention that CBD may confer greater therapeutic effects in a more compromised brain.

Our findings suggest a restorative effect of CBD on hippocampal substructures in cannabis users, even within the context of continued cannabis use. In the absence of ongoing use, as might occur in a motivated treatment-seeking sample, greater neurotherapeutic benefit may be expected. During the trial, participants reported feeling less high after using cannabis and this was corroborated by significant reduction at post-treatment on the CEQ Euphoria subscale. As such, CBD may be a valuable adjunct to psychological treatments for cannabis dependence. Furthermore, subjective ratings of preferred level of cannabis intoxication were negatively associated with increased subicular region growth.

A critical limitation of this study was that it was a pragmatic, open-label trial without a placebo control. While it is unlikely that brain structural measures are amenable to expectancy effects, our findings should nevertheless be interpreted with caution. In addition, the sample was relatively high-functioning, and some participants\' cannabis use was infrequent. If therapeutic effects of CBD are more likely to manifest in a disease state, this gives even greater credence to our findings and stronger effects may be expected in a more entrenched sample. As the majority of participants were young adult males, the influence of ongoing brain maturation must be considered and future research should examine age effects as well as potential sex differences in CBD treatment effects. That some hippocampal subfield volume changes were associated with plasma CBD concentrations supports the changes being CBD treatment related. Nevertheless, replication in a larger sample placebo-controlled trial is warranted.

The mechanisms underlying a restorative effect of CBD on hippocampal subfields in cannabis users remain to be elucidated. While neurogenesis is plausible, no change was observed in the DG, the primary hippocampal subregion implicated in neurogenesis. The potential involvement of both CB1Rs and glutamate is worthy of further investigation, given the high density of cannabinoid receptors in the subicular complex and CA1 regions,^[@B15]^ and evidence suggesting glutamatergic dysregulation to be a driver of subicular and CA1 volume changes associated with psychosis.^[@B72],[@B73]^ The differential pattern of volume change observed across left and right hippocampi is also of interest. While the majority of studies examining cannabis-related hippocampal pathophysiology which have reported hemispheric lateralization effects found volume reduction to be more pronounced in the right hippocampus,^[@B10],[@B80],[@B81]^ inverse associations between left hippocampal volume and cannabis exposure (e.g., cumulative use^[@B9]^ and quantity per week^[@B82]^) have also been reported. Mechanisms for hemispheric differentiation remain unclear, and future research should seek to examine potential lateralization effects in CBD treatment response.

In conclusion, our findings are the first to demonstrate an ameliorating effect of CBD treatment upon brain structural harms characteristic of regular cannabis use. Furthermore, these results speak to the potential for CBD treatment to restore hippocampal pathology in a range of clinical populations (e.g., schizophrenia, Alzheimer\'s disease, and major depressive disorder).
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ANCOVA

:   analysis of covariance

AUDIT

:   Alcohol Use Disorders Identification Test

BDI

:   Beck Depression Inventory

BMI

:   body mass index

CA

:   cornu ammonis

CAPE

:   Community Assessment of Psychic Experiences

CB1Rs

:   Cannabinoid type 1 receptors

CBD

:   cannabidiol

CEQ

:   Cannabis Experiences Questionnaire

DG

:   dentate gyrus

GC-ML-DG

:   granule cells in the molecular layer of the dentate gyrus

HATA

:   hippocampal-amygdaloid transition area

IQ

:   intelligence quotient

ML-DG

:   molecular layer of the dentate gyrus

MRI

:   magnetic resonance imaging

NAA

:   n-acetylaspartate

RAVLT

:   Rey Auditory Verbal Learning Test

SD

:   standard deviation

SDS

:   Severity of Dependence Scale

STAI

:   State Trait Anxiety Index

THC

:   Δ^9^-tetrahydrocannabinol
